The passing of renowned pathologist and former Australian of the Year, Richard Scolyer, has left a profound impact on the nation, with his colleagues and friends remembering him as a man of immense energy and dedication. At just 59 years old, Scolyer's battle with glioblastoma, an aggressive brain cancer, came to an end on June 7th, sparking a wave of tributes and a renewed focus on brain cancer research.
Scolyer's legacy is one of unwavering commitment to his field. As a prominent advocate for research and funding, he played a pivotal role in pioneering world-first treatments for melanomas alongside his colleague, Georgina Long. His indomitable spirit and relentless pursuit of knowledge were evident in his numerous endeavors, from running and triathlons to his academic lectures and raising a family.
Lisa Horvath, Chris O'Brien Lifehouse chief clinical officer and director of research, described Scolyer's energy as 'massive'. She recalled his relentless drive, always thinking of the next research question, and his ability to juggle multiple responsibilities with ease. Horvath's tribute highlights Scolyer's passion and his desire to leave a lasting impact.
Michael Boyer, Chris O'Brien Lifehouse chief executive, echoed this sentiment, emphasizing Scolyer's 'can-do attitude'. He described his legacy as an approach to problems, emphasizing the importance of trying, not giving up, and doing what you can. This mindset, Boyer suggests, is what made Scolyer such an exceptional figure.
The impact of Scolyer's work extends beyond his personal achievements. Horvath and Boyer announced a new brain cancer research position in his name, funded by a substantial $5.9 million grant. This initiative will support a team comprising a chair of brain cancer research, researchers, and PhD students, along with expanded clinical trials.
The establishment of this chair, Horvath explained, is a collaboration between Chris O'Brien Lifehouse, the University of Sydney, and the Royal Prince Alfred Hospital. The goal is to appoint a clinician scientist, someone who embodies Scolyer's patient-focused approach and excels in research. This individual will be tasked with bringing innovative ideas to the forefront, ultimately leading to new treatments for brain cancers.
Horvath expressed her hope that this chair will ensure Scolyer's legacy remains 'incredibly productive' and that his contributions will be a source of pride. She emphasized the importance of honoring Scolyer's memory through continued research and innovation, ensuring that his impact on the field of oncology endures.
In conclusion, Richard Scolyer's life and work have left an indelible mark on the Australian community and the global medical community. His passing has sparked a renewed focus on brain cancer research, and his legacy will continue to inspire and guide those who follow in his footsteps. As Horvath and Boyer urge, donations to Chris O'Brien Lifehouse will help sustain Scolyer's vision and ensure his impact continues to be felt for generations to come.
